Citron Exposes the Clinical Study Cyberdyne Does Not Want You To See- We Reaffirm Price Target 300¥

In this recent report, Citron exposes the clinical study conducted by Cyberdyne that shows that patients who use the HAL have minimal better outcomes than those who use a simple hospital hoist system. The clinical report also details that over 65% of people who use HAL experience some adverse events. Citron believes this is the reason why the company has not submitted anything to the FDA and more importantly the reason why the HAL has not achieved any meaningful sales in either Japan or Europe. We believe this clinical study to be the smoking gun on why Cyberdyne is on its way to 300¥ per share.